A detailed history of Teacher Retirement System Of Texas transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Teacher Retirement System Of Texas holds 21,430 shares of FATE stock, worth $51,860. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,430
Previous 19,999 7.16%
Holding current value
$51,860
Previous $66,000 13.64%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.12 - $5.57 $4,464 - $7,970
1,431 Added 7.16%
21,430 $75,000
Q2 2024

Aug 09, 2024

BUY
$3.26 - $7.08 $65,196 - $141,592
19,999 New
19,999 $66,000
Q3 2023

Oct 31, 2023

BUY
$2.02 - $5.04 $2,110 - $5,266
1,045 Added 4.91%
22,348 $47,000
Q2 2023

Jul 19, 2023

SELL
$4.76 - $6.59 $12,585 - $17,423
-2,644 Reduced 11.04%
21,303 $101,000
Q1 2023

May 12, 2023

BUY
$4.24 - $11.12 $1,543 - $4,047
364 Added 1.54%
23,947 $136,000
Q4 2022

Feb 10, 2023

SELL
$9.86 - $23.83 $16,860 - $40,749
-1,710 Reduced 6.76%
23,583 $238,000
Q3 2022

Nov 03, 2022

BUY
$21.04 - $36.06 $275,182 - $471,628
13,079 Added 107.08%
25,293 $567,000
Q2 2022

Aug 09, 2022

SELL
$17.78 - $42.39 $63,243 - $150,781
-3,557 Reduced 22.55%
12,214 $303,000
Q1 2022

May 09, 2022

BUY
$29.67 - $60.28 $31,895 - $64,801
1,075 Added 7.31%
15,771 $611,000
Q4 2021

Feb 10, 2022

BUY
$47.84 - $64.34 $133,138 - $179,058
2,783 Added 23.36%
14,696 $860,000
Q3 2021

Nov 09, 2021

BUY
$59.27 - $95.73 $177,513 - $286,711
2,995 Added 33.58%
11,913 $706,000
Q2 2021

Aug 05, 2021

BUY
$67.25 - $92.52 $91,863 - $126,382
1,366 Added 18.09%
8,918 $774,000
Q1 2021

May 11, 2021

BUY
$72.16 - $117.4 $101,817 - $165,651
1,411 Added 22.98%
7,552 $623,000
Q4 2020

Feb 11, 2021

BUY
$38.09 - $100.95 $233,910 - $619,933
6,141 New
6,141 $558,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $235M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Teacher Retirement System Of Texas Portfolio

Follow Teacher Retirement System Of Texas and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Teacher Retirement System Of Texas, based on Form 13F filings with the SEC.

News

Stay updated on Teacher Retirement System Of Texas with notifications on news.